🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

162 results for “Fondazione” Clear

  1. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Fondazione Telethon ETS

    NSCLC non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  2. INAVOLISIB

    Fondazione Telethon ETS

    endometrial cancer

    phase 2 small molecule active

    1 trial

  3. INDOCYANINE GREEN

    Fondazione Telethon ETS

    Patients with gynecological cancers undergoing pelvic exenteration

    phase 2 small molecule active

    1 trial

  4. IPSTYL “120 mg soluzione iniettabile in siringa preriempita”, METFORMINA TEVA 850 mg compresse rivestite con film

    Fondazione Telethon ETS

    advanced progressive gastro-intestinal or lung carcinoids

    phase 2 small molecule active

    1 trial

  5. IRINOTECAN, FLUOROURACIL , CETUXIMAB , ENCORAFENIB , SODIUM FOLINATE

    Fondazione Telethon ETS

    Patients affected by mCRC harbouring BRAF V600E

    phase 2 small molecule active

    1 trial

  6. JEMPERLI 500 mg concentrate for solution for infusion, Zejula 100 mg film-coated tablets, Zejula 100 mg film-coated tablets

    Fondazione Telethon ETS

    HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  7. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Fondazione Telethon ETS

    Recurrent, platinum-resistant, CPS >1 positive ovarian, Fallopian tube and primary peritoneal cancer patients

    phase 2 small molecule active

    1 trial

  8. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Fondazione Telethon ETS

    high-risk soft tissue sarcoma of the extremity (undifferentiated pleomorphic sarcoma or dedifferentiated/pleomorphic liposarcoma, tumor size > 5 cm, grade 2 or 3 out of 3)

    phase 2 small molecule active

    1 trial

  9. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Fondazione Telethon ETS

    Patients with pre neoplastic high grade HPV-related vulvar and cervical lesions

    phase 2 small molecule active

    1 trial

  10. KEYTRUDA 25 mg/mL concentrate for solution for infusion, ENFORTUMAB VEDOTIN

    Fondazione Telethon ETS

    Collecting Duct Carcinoma, Medullary Renal cell Carcinoma

    phase 2 small molecule active

    1 trial

  11. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, Olaparib

    Fondazione Telethon ETS

    Adult patients affected by recurrent/metastatic, platinum resistant nasopharyngeal cancer

    phase 2 small molecule active

    1 trial

  12. KEYTRUDA 25 mg/mL concentrate for solution for infusion, TEMOZOLOMIDE, TEMOZOLOMIDE

    Fondazione Telethon ETS

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  13. LIMBAL STEM CELLS, AUTOLOGOUS

    Fondazione Telethon ETS

    low back pain

    phase 2 small molecule active

    1 trial

  14. Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion., Lenvatinib

    Fondazione Telethon ETS

    vulvar cancer

    phase 2 small molecule active

    1 trial

  15. Lenvatinib, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Fondazione Telethon ETS

    Advanced unresectable classic Kaposi sarcoma relapsed and/or refractory to previous standard treatments.

    phase 2 small molecule active

    1 trial

  16. Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets

    Fondazione Telethon ETS

    BRCA wild-type advanced ovarian, fallopian tube and primitive peritoneal cancer

    phase 2 small molecule active

    1 trial

  17. Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets

    Fondazione Telethon ETS

    recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes

    phase 2 small molecule active

    1 trial

  18. MERCAPTOPURINE, PREDNISONE, VINCRISTINE SULFATE, CYTARABINE, FILGRASTIM, LENOGRASTIM, CYTARABINE, IDARUBICIN HYDROCHLORIDE, FOLINIC ACID, Iclusig 15 mg film-coated tablets, METHYLPREDNISOLONE SODIUM SUCCINATE, CYCLOPHOSPHAMIDE, METHOTREXATE, METHOTREXATE, DEXAMETHASONE DISODIUM PHOSPHATE, Iclusig 15 mg film-coated tablets

    Fondazione Telethon ETS

    Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.

    phase 2 small molecule active

    1 trial

  19. METFORAL 850 mg compresse rivestite con film

    Fondazione Telethon ETS

    Triple negative breast cancer

    phase 2 small molecule active

    1 trial

  20. Mosunetuzumab, Mosunetuzumab, TOCILIZUMAB , BRUKINSA 80 mg hard capsules

    Fondazione Telethon ETS

    Follicular lymphoma

    phase 2 small molecule active

    1 trial

  21. NEXPOVIO 20 mg film-coated tablets, HOLOXAN 1 g polvere per soluzione per infusione, Decadron “8 mg/2 ml Soluzione iniettabile”, ETOPOSIDE TEVA 20 mg/ml, concentrato per soluzione per infusione.

    Fondazione Telethon ETS

    Relapsed or Refractory Peripheral T-cell Lymphomas

    phase 2 small molecule active

    1 trial

  22. NIMOTUZUMAB, NAVELBINE 10 mg/ml concentrato per soluzione per infusione

    Fondazione Telethon ETS

    Diffuse intrinsic pontine glioma

    phase 2 small molecule active

    1 trial

  23. NIVOLUMAB, TEDOPI

    Fondazione Telethon ETS

    metastatic non-small-cell lung cancer

    phase 2 small molecule active

    1 trial

  24. Normix 200 mg compresse rivestite con film, The placebo is a film-coated oral tablet designed to be comparable in appearance, administration, and handling to the investigational medicinal product (rifaximin 200 mg film-coated tablets), while containing no active pharmaceutical ingredient. The placebo consists exclusively of commonly used pharmaceutical excipients with established safety profiles and is administered solely to maintain blinding in the clinical trial.

    Fondazione Telethon ETS

    substance use disorder

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources